Browsing NTNU Open by Author "Fallon, Marie"

Now showing items 1-5 of 5

    • A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer 

      Solheim, Tora Skeidsvoll; Laird, Barry J; Balstad, Trude Rakel; Stene, Guro Birgitte; Bye, Asta; Johns, Neil; Pettersen, Caroline Hild Hakvåg; Fallon, Marie; Fayers, Peter; Fearon, Kenneth; Kaasa, Stein (Journal article; Peer reviewed, 2017)
      Background: Cancer cachexia is a syndrome of weight loss (including muscle and fat), anorexia, and decreased physical function. It has been suggested that the optimal treatment for cachexia should be a multimodal intervention. ...

    • Appetite and dietary intake endpoints in cancer cachexia clinical trials: Systematic Review 2 of the cachexia endpoints series 

      Vagnildhaug, Ola Magne; Balstad, Trude Rakel; Ottestad, Inger; Bye, Asta; Greil, Christine; Arends, Jann; Baracos, Vickie; Brown, Leo R.; Dajani, Olav; Dolan, Ross D.; Fallon, Marie; Fraser, Eilidh; Grzyb, Aleksandra; Hjermstad, Marianne Jensen; Jakobsen, Gunnhild; Kaasa, Stein; McDonald, James; Philips, Iain; Sayers, Judith; Simpson, Melanie Rae; Sousa, Mariana S.; Skipworth, Richard J.E.; Laird, Barry J.A.; Solheim, Tora S (Journal article; Peer reviewed, 2024)
      There is no consensus on the optimal endpoint(s) in cancer cachexia trials. Endpoint variation is an obstacle when comparing interventions and their clinical value. The aim of this systematic review was to summarize and ...

    • Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series 

      Yule, Michael S.; Thompson, Joshua; Leesahatsawat, Khachonphat; Sousa, Mariana S.; Anker, Stefan D.; Arends, Jann; Balstad, Trude Rakel; Brown, Leo R.; Bye, Asta; Dajani, Olav; Fallon, Marie; Hjermstad, Marianne Jensen; Jakobsen, Gunnhild; McDonald, James; McGovern, Josh; Roeland, Eric J.; Sayers, Judith; Skipworth, Richard J.E.; Ottestad, Inger; Philips, Iain; Simpson, Melanie Rae; Solheim, Tora S; Vagnildhaug, Ola Magne; McMillan, Donald; Laird, Barry J; Dolan, Ross D. (Journal article; Peer reviewed, 2024)
      Regulatory agencies require evidence that endpoints correlate with clinical benefit before they can be used to approve drugs. Biomarkers are often considered surrogate endpoints. In cancer cachexia trials, the measurement ...

    • Cancer cachexia: Rationale for the MENAC (Multimodal - Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial 

      Solheim, Tora Skeidsvoll; Laird, Barry J. A.; Balstad, Trude Rakel; Bye, Asta; Stene, Guro Birgitte; Baracos, Vickie; Strasser, Florian; Griffiths, Gareth; Maddocks, Matthew; Fallon, Marie; Kaasa, Stein; Fearon, Kenneth (Journal article; Peer reviewed, 2018)
      Cancer cachexia is a multifactorial syndrome characterised by an ongoing loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support alone. Cachexia has a high prevalence in cancer and a ...

    • A systematic review examining nutrition support interventions in patients with incurable cancer 

      Blackwood, Honor A.; Hall, Charlie C.; Balstad, Trude Rakel; Solheim, Tora Skeidsvoll; Fallon, Marie; Haraldsdottir, Erna; Laird, Barry J (Peer reviewed; Journal article, 2019)
      Purpose Recent guidelines by the European Society for Clinical Nutrition and Metabolism (ESPEN) have advocated increased attention to nutritional support in all patients with cancer; however, little is known about the ...